. 2020 Nov 21;2020:8816737. doi: 10.1155/2020/8816737

(b).

Intervention (mean)	Recurrence	Refractory	AEs	Use of concurrent (anti-TNF)
Fixed cell dose	7 months without recurrence	Yes		Yes
First: 2 × 10⁷ MSCs
Second: 4 × 10⁷ MSCs
Fixed cell dose	Two completely healed patients were followed up for 4 years without recurrence	Yes		Yes
First: 2 × 10⁷ MSCs
Second: 4 × 10⁷ MSCs
Fixed cell dose	Unknown	Yes		No
First: 2 × 10⁷ MSCs
Second: 4 × 10⁷ MSCs
Fixed cell dose	24 w without recurrence	Yes		Yes
A: 1 × 10⁷ MSCs
B: 3 × 10⁷ MSCs
C: 9 × 10⁷ MSCs
Fixed cell dose	Being follow-up	Yes	68/103 in MSCs vs. 66/102 in placebo at 24 w	Yes
12 × 10⁷ MSCs	Being follow-up		68/103 in MSCs vs. 66/102 in placebo at 24 w
Fixed cell dose	Being follow-up	Yes	79/103 in MSCs vs. 74/102 in placebo at 52 w	Yes
12 × 10⁷ MSCs	Being follow-up	Yes	79/103 in MSCs vs. 74/102 in placebo at 52 w	Yes
Fixed cell dose	Recurrence of the fistula was observed at 2-year follow-up in eight previously cured patients	Unknown	7/23 MSCs+fibrin glue vs. 9/21 fibrin glue	No
First: 10 × 10⁷ MSCs
Second: 10 × 10⁷ MSCs